Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis

Jiyi Xie1,2†, Cong Zhang1,2†, Shijun Li1,2, Rong Dai1,2, Mitchell A. Sullivan3, Bin Deng1,2, Qiling Xu1,2, Jinglin Wang1,2*, Chen Shi1,2* and Yu Zhang1,2*

1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China, 3 Glycation and Diabetes Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia

Background: In China, thalidomide (THD) has been used to prevent chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC); however, there is limited evidence on the efficacy and safety of THD in this setting. The aim of this study was to evaluate the efficacy, safety, and impact on quality of life (QoL) of THD on CINV following HEC.

Methods: Electronic databases were systematically searched for all randomized controlled trials (RCTs) in HEC using THD. The primary outcomes were complete response (CR) and no nausea, Secondary outcomes were the incidence of adverse events and QoL related indicators. We calculated risk ratios (RRs) and 95% confidence intervals (CIs) using a fixed-effects model. In the case of heterogeneity ($I^2 \geq 50\%$), a random-effects model was performed.

Results: A total of 3168 patients were included from 34 RCTs. In terms of CR rate, THD plus 5-HT3 receptor antagonist (5-HT3RA) with or without dexamethasone (DEX) was significantly higher than 5-HT3RA with or without DEX in the acute phase (74.4% vs 67.4%; RR 1.10), delayed phase (70.6% vs 50.4%; RR 1.53), and overall phase (68.4% vs 53.4%; RR 1.28). In terms of no nausea rate, the THD group was also significantly higher than the control group in the acute phase (61.7% vs 55.5%; RR 1.12), delayed phase (50.5% vs 30.0%; RR 1.69), and overall phase (44.6% vs 29.9%; RR 1.50). There was no statistical difference in the incidence of fatigue, headache, diarrhea, rash, hepato renal...
1 INTRODUCTION

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common disturbing adverse effects of anticancer chemotherapy, which can significantly impair the patient’s quality of life (QoL), adherence with future therapy, and nutritional status. American Society of Clinical Oncology (ASCO) guideline (2020) (1) classify chemotherapeutic agents according to their emetogenic potential (high, medium, low and minimal) and make recommendations based on their level of risk. For patients receiving highly emetogenic chemotherapy (HEC; CINV risk >90%), such as cisplatin- and anthracycline/cyclophosphamide (AC)-based regimens, National Comprehensive Cancer Network (NCCN) antiemesis guideline recommend a four-drug combination of a 5-HT3 receptor antagonist (5-HT3RA), a neurokinin-1 (NK1) RA, dexamethasone (DEX), and olanzapine (2). Even if CINV prevention is now dramatically improved, there is still a need to find more effective, safer and more economical drug regimens for better prevention because CINV remains a frequent and feared adverse effect.

The unintended teratogenic effect of thalidomide (THD), prescribed to treat morning sickness in pregnant women, is a historic tragedy, however with the approval of this drug for indications such as multiple myeloma. A randomized controlled double-blind phase III clinical study (3) in the Chinese population suggested that THD combined with palonosetron and DEX is efficacious and well-tolerated for the prevention of delayed CINV in anticancer chemotherapy-naive patients who undergo HEC. Rates of complete response and no nausea in the delayed phase were higher and adverse effects were mild to moderate in the THD group. Since pregnancy and childbirth are nearly impossible during anticancer chemotherapy in patients with malignant tumors, and THD prices are relatively low in China, there is some potential for THD to be useful in the management of CINV.

In China, there have been many controlled clinical trials using THD, in addition with antiemetic regimens, with results showing that THD can be used as a complementary and alternative medicine to prevent CINV following HEC. However, there is no systematic review or meta-analysis of its efficacy in the prevention of CINV, the incidence of adverse effects, and the improvement of QoL under HEC. Therefore, all controlled clinical trials using THD under HEC were systematically evaluated for efficacy in the prevention of CINV through multiple studies and large sample size.

2 METHODS

The meta-analysis was pre-registered at PROSPERO (CRD42020158732).

2.1 Literature Search

This systematic review and meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (4). Relevant publications were searched in the Chinese National Knowledge Infrastructure (CNKI), the VIP Information Database, Wanfang Database, PubMed, EMBASE, and the Cochrane Library. The systematic review was performed in December 2019 and updated in August 2020.

The keywords for searching included: “chemotherapy-induced nausea and vomiting”, “CINV”, “vomit”, “emesis”, “thalidomide”, “highly emetogenic chemotherapy”, “CDDP”, “cisplatin”, or “anthracycline and cyclophosphamide”. References of the selected articles were also checked to identify further eligible trials.

2.2 Study Selection Criteria

Selecting studies that met the inclusion and exclusion criteria was independently performed by two authors (JX, CZ). Any disagreement between reviewers was resolved through public discussions until a consensus was reached.

Inclusion criteria: (a) randomized controlled trials (RCTs) in patients who received HEC (such as cisplatin-based treatment or AC regimen); (b) studies that reported either THD as an add-on treatment (5-HT3RA, with or without DEX) or THD monotherapy compared to standard treatment.

Exclusion criteria: (a) review articles or studies involving non-human subjects; (b) duplicate published articles; (c) studies where anticancer chemotherapy regimens and basic antiemetic regimens were inconsistent between experimental and control groups; (d) studies with a high risk of bias.

2.3 Outcomes

The primary outcomes: Complete response (CR) and no nausea. CR is defined as having no emetic episode and requiring no use of rescue medication. Nausea was categorized by using a 4-point Likert scale (0, no symptoms; 3, severe). CR and no nausea were measured in the acute phase (0-24 h), the delayed phase (24-120 h), and the overall phase (0-120 h). Secondary outcomes included the adverse events which was graded according to the common terminology criteria for adverse events (CTCAE) (5) and indicators...
related to QoL: Karnofsky performance scale (KPS) scores, weight, appetite, and sleep quality.

### 2.4 Quality Assessment

The quality of the included studies was assessed independently by two authors (SL, RD) based on the Cochrane Handbook for Systematic Review of Interventions (6). The Cochrane Collaboration’s tool for assessing the risk of bias for RCTs includes the following seven items: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessments (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias. Each item was described as high risk of bias, low risk of bias, or unclear risk of bias. Disagreements were discussed and resolved by consensus between both reviewers or via consultation with a third reviewer (JX).

### 2.5 Statistical Analysis

Results were quantitatively synthesized by means of meta-analysis using the Review Manager (version 5.3; Cochrane Collaboration, Oxford, England). The Mantel-Haenszel method was used to estimate the pooled risk ratio (RR) for each dichotomous variable. I^2 was used to evaluate heterogeneity across studies. When heterogeneity (I^2 ≥ 50%) was detected, random-effects meta-analyses were performed. I^2 < 50%, a fixed effect statistical model was used. Results obtained from the analyses were displayed by generating a forest plot. A p-value of < 0.05 was considered statistically significant.

### 3 RESULTS

#### 3.1 Study Selection and Trial Characteristics

There were 898 records identified via database searching. 537 of the records were searched in PubMed, EMBASE, and the Cochrane library, 361 of the records were searched in the CNKI, VIP Information Database, and Wanfang Database (Figure 1).

After removing the duplicates, there were 462 results. The titles and abstracts of 462 studies were screened, and the full text of 61 articles was reviewed. 27 studies were excluded for the following reasons: not a RCT study (n = 10), not HEC (n = 11), a different outcome (n = 5), and same data source (n = 1). Finally, 34 studies were assessed for eligibility and included in the quantitative synthesis. A total of 3168 patients were included. The characteristics of the included studies are shown in Table 1. All studies were RCTs. Patients’ tumor types include breast, gastric, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), cervical, and others. All patients in these studies received HEC.

The included studies contained a total of 8 outcomes: CR (acute phase) (3, 9, 10, 14–18); CR (delayed phase) (3, 7, 9–12, 14, 16, 17); CR (overall phase) (3, 8, 9, 13); no nausea (acute phase) (3, 9, 10, 14, 16–18); no nausea (delayed phase) (3, 9, 10, 14, 16–18); no nausea (overall phase) (3, 9, 18); adverse events (3, 7, 9–19, 21–26, 28–33, 37–39); QoL (12, 13, 17, 20–23, 26, 27, 34–36).

#### 3.2 Risk of Bias and Quality Assessment

All of the included studies had a low risk of attrition bias and reporting bias. Only one study (25) had a high risk of performance bias and detection bias due to its single-blind method. Two of the included studies (28 and 39) had a high risk of other bias due to a possible conflict of interest or small sample size (Figure 2).

#### 3.3 Primary Outcomes

##### 3.3.1 CR in the Acute Phase

Data of CR in the acute phase were available in 7 studies, including 1071 patients: 531 patients in the experimental group were treated with THD added to the 5-HT3RA-based conventional antiemetic regimen, and 540 patients in the control group were treated with the 5-HT3RA-based conventional antiemetic regimen. The CR rate was significantly higher with the addition of THD in the acute phase: 74.4% vs 67.4% (RR 1.10, 95%CI 1.03–1.18, p = 0.008), without significant heterogeneity among studies (I^2 = 19%) (Figure 3).

##### 3.3.2 CR in the Delayed Phase

Data of CR in the delayed phase were available in 9 studies, including 1270 patients: 633 patients in the experimental group and 637 patients in the control group. The CR rate was significantly higher with the addition of THD in the delayed phase: 70.6% vs 50.4% (RR 1.53, 95%CI 1.28–1.82, p < 0.00001), with significant heterogeneity among studies (I^2 = 54%). Due to significant heterogeneity among the studies, a random-effects model was chosen for analysis (Figure 4).

##### 3.3.3 CR in the Overall Phase

Data of CR in the overall phase were available in 4 studies, including 870 patients: 434 patients in the experimental group and 436 patients in the control group. The CR rate was significantly higher with the addition of THD in the overall phase: 68.4% vs 53.4% (RR 1.28, 95%CI 1.15–1.43, p < 0.00001), without significant heterogeneity among studies (I^2 = 9%) (Figure 5).

##### 3.3.4 No Nausea in the Acute Phase

Data of no nausea in the acute phase were available in 7 studies, including 1291 patients: 648 patients in the experimental group and 643 patients in the control group. The no nausea rate was significantly higher with the addition of THD in the acute phase: 61.7% vs 55.5% (RR 1.12, 95%CI 1.02–1.22, p = 0.02), without significant heterogeneity among studies (I^2 = 0%) (Figure 6).

##### 3.3.5 No Nausea in the Delayed Phase

Data of no nausea in the delayed phase were available in 7 studies, including 1291 patients: 648 patients in the experimental group and 643 patients in the control group. The no nausea rate was significantly higher with the addition of THD in the delayed phase: 50.5% vs 30.0% (RR 1.69, 95%CI 0.96–2.95).
1.47-1.94, p<0.00001), without significant heterogeneity among studies (I²=42%) (Figure 7).

3.3.6 No Nausea in the Overall Phase
Data of no nausea in the overall phase were available in 3 studies, including 987 patients: 495 patients in the experimental group and 492 patients in the control group. The no nausea rate was significantly higher with the addition of THD in the overall phase: 44.6% vs 29.9% (RR 1.50, 95%CI 1.27-1.77, p<0.00001), without significant heterogeneity among studies (I²=3%) (Figure 8).

3.4 Secondary Outcomes
3.4.1 Adverse Events
Data from 28 out of the 34 included articles involved safety studies of THD and 11 adverse events were included: fatigue (12 studies), constipation (26 studies), mucositis (7 studies), headache (5 studies), diarrhea (7 studies), rash (11 studies), peripheral neuropathy (9 studies), hepatorenal damage (13 studies), myelosuppression (7 studies), somnolence (13 studies), and anorexia (3 studies). There was no significant
heterogeneity among all studies (I²<50%) and all analyses were performed using a fixed-effects model.

The incidence of mucositis and anorexia was significantly lower with the addition of THD: namely, 14.6% vs 23.3% (RR 0.64, 95%CI 0.46–0.88, p=0.006) of mucositis; and 19.6% vs 37.4% (RR 0.52, 95%CI 0.34–0.81, p=0.003) of anorexia.

The incidence of constipation, peripheral neuropathy, and somnolence was significantly higher with the addition of THD: namely, 39.5% vs 26.9% (RR 1.45, 95%CI 1.30–1.61, p<0.00001) of constipation; 27.4% vs 16.2% (RR 1.61, 95%CI 1.25–2.08, p=0.0002) of peripheral neuropathy; and 25.9% vs 10.2% (RR 2.41, 95%CI 1.78–3.28, p<0.00001) of somnolence.

There was no statistical difference in the incidence of fatigue, headache, diarrhea, rash, hepatorenal damage, and myelosuppression between those with and without THD (p>0.05) (Table 2).

### Table 1: Characteristics of studies included.

| Study                        | T/C(n) | Cancer Types          | Chemotherapy Regimens | Interventions                          | Control | Outcomes |
|------------------------------|--------|-----------------------|-----------------------|----------------------------------------|---------|----------|
| Cheng et al. (7)             | 45/45  | Cervical              | CDDP                  | THD(D0-4:50mg qn)+TRO+DEX              | TRO+DEX | (2)(7)   |
| Wang (8)                     | 40/40  | Lung                  | CDDP-containing       | THD(100mg qn)+PAL+DEX                 | PAL+DEX | (3)      |
| Song et al. (9)              | 40/40  | Gastric/Lung/Cervical/Other | CDDP                  | THD(D1-5:100mg qd)+OND+MET+DEX        | OND+MET+DEX | (1)(2)(3)(4)(5) |
| Zhang et al. (3)             | 317/321| Lung/Breast/Other     | CDDP-containing/AC    | THD(D2-4:100mg bid)+PAL+DEX           | PAL+DEX | (1)(2)(3)(4)(5) |
| Li et al. (10)               | 30/30  | Lung                  | CDDP-containing       | THD(D1-5:100mg qn)+OND+DEX            | OND+DEX | (1)(2)(4)(5)(7) |
| Zhao et al. (11)             | 39/39  | Unknown               | CDDP-containing/AC    | THD(25mg bid)+TRO+DEX                 | TRO+DEX | (2)(7)   |
| Han et al. (12)              | 40/38  | Gastric/Lung/Ovarian  | CDDP-containing       | THD(D0:100mg qn,50mg was added per night up to 200 mg)+AZA | AZA     | (2)(7)(8) |
| Han et al. (13)              | 38/32  | Gastric/Lung/Ovarian  | CDDP-containing       | THD(D0:100mg qn,50mg was added per night up to 200 mg)+TRO | TRO     | (3)(7)(8) |
| Zuo (14)                     | 41/40  | Breast                | GP                    | THD(D1-8:25mg bid)+TRO                | TRO     | (1)(2)(4)(5)(7) |
| Cui et al. (15)              | 21/25  | Breast                | AC                    | THD(D1)-TRO                           | TRO     | (1)(7)   |
| Yu et al. (16)               | 30/31  | NSCLC                 | GP                    | THD(D1)-5:50mg bid+RAM+MET             | RAM+MET | (1)(2)(4)(5)(7) |
| Zhang et al. (17)            | 52/50  | SCLC                  | CDDP-containing       | THD(D1-5:100mg qn)+PAL+MP             | PAL+MP  | (1)(2)(4)(5)(7) |
| Jiang (18)                   | 138/128| Lung/Breast           | CDDP-containing/AC    | THD(D1-5:100mg bid)+PAL+DEX           | PAL+DEX | (4)(5)(6)(7) |
| Xing et al. (19)             | 38/38  | Gastric               | DP                    | THD(D1-7:100mg qd)                    | Placebo | (7)      |
| Luo (20)                     | 26/28  | NSCLC                 | GP                    | THD(D1-7:100mg qd D8-42: 200mg qd)     | Placebo | (8)      |
| Niu et al. (21)              | 32/28  | Gastric               | TP                    | THD(D1-42: 100mg qn)                  | Placebo | (7)(18)  |
| Peng et al. (22)             | 51/53  | NSCLC                 | TP                    | THD(D1-7:100mg qn D8-90:200mg qn)+5-HT,RA | 5-HT,RA | (7)(8)   |
| Peng et al. (23)             | 30/31  | NSCLC                 | TP                    | THD(D1-7:100mg qn D8-90:200mg qn)+5-HT,RA | 5-HT,RA | (7)(8)   |
| He et al. (24)               | 19/20  | NSCLC                 | NP                    | THD(D1-7:100mg qn D8-14:150mg qn D15-90: 200mg qn)+GRA | GRA     | (7)      |
| Zhang (25)                   | 48/48  | NSCLC                 | TP                    | THD(D1-7:100mg qd D8-84:200mg qd)+5-HT,RA | 5-HT,RA | (7)      |
| Gu et al. (26)               | 33/33  | NSCLC                 | NP                    | THD(200mg qd)                         | Placebo | (7)(8)   |
| Huang (27)                   | 36/30  | NSCLC                 | GP                    | THD(D1-30:200mg qn)+5-HT,RA           | 5-HT,RA | (8)      |
| Pujol et al. (28)            | 49/43  | SCLC                  | PCDE                  | THD(D1-112: 400mg qd)                 | Placebo | (7)      |
| Sun and Xu (29)              | 30/30  | NSCLC                 | DP                    | THD(D1-7:100mg qd D8-90:300mg qd)+GRA+DEX | GRA+DEX | (7)      |
| Liang (30)                   | 35/31  | NSCLC                 | CDDP-containing       | THD+                                | Placebo | (7)      |
| Wang et al. (31)             | 60/60  | NSCLC                 | GP                    | THD(D1-180:200mg qn)+5-HT,RA          | 5-HT,RA | (7)      |
| Zuo (32)                     | 37/37  | SCLC                  | EP                    | THD(D6-21: 100mg/m² 21d for 1 cycle, total 6 cycles of treatment) | Placebo | (7)      |
| Xie et al. (33)              | 29/29  | Breast                | GP                    | THD(D1)+5-HT,RA                       | 5-HT,RA | (7)      |
| Dong (34)                    | 30/30  | NSCLC                 | TP                    | THD(D1)+5-HT,RA                       | 5-HT,RA | (8)      |
| Huang and Wu (35)            | 30/30  | NSCLC                 | TP                    | THD(D1-7:100mg qd D8-84:200mg qd)      | Placebo | (8)      |
| Liu et al. (36)              | 40/40  | NSCLC                 | TP                    | THD(D1-7:100mg qd D8-90:200mg qd)+5-HT,RA | 5-HT,RA | (8)      |
| Jiang et al. (37)            | 31/30  | NSCLC                 | GP                    | THD(D1-60:200mg qn)+AZA                | AZA     | (7)      |
| Sun et al. (38)              | 36/21  | NSCLC                 | NP                    | THD(D1-21:100mg bid)                  | Placebo | (7)      |
| Shen et al. (39)             | 15/10  | NSCLC                 | NP                    | THD(D1)                              | Placebo | (7)      |

**NSCLC**, Non-small cell lung cancer; **SCLC**, Small cell lung cancer; **CDDP**, Cisplatin; **AC**, Anthracycline + Cyclophosphamide; **GP**, Gemcitabine+Cisplatin; **DP**, Docetaxel+Cisplatin; **TP**, Paclitaxel+Cisplatin; **NP**, Vinorelbine+Cisplatin; **PCDE**, Etoposide+Cisplatin+Cyclophosphamide+4-epidoxorubicin; **EP**, Etoposide+Cisplatin; **THD**, Thalidomide; **TRO**, Tropisetron; **DEX**, Dexamethasone; **PAL**, Palonosetron; **OND**, Ondansetron; **MET**, Metoclopramide; **AZA**, Azasetron; **RAM**, Ramosetron; **MP**, Methylprednisolone; **GRA**, Granisetron; **5-HT,RA**, 5-HT, receptor antagonist; (1): Complete response (acute phase); (2): Complete response (delayed phase); (3): Complete response (overall phase); (4): No nausea (acute phase); (5): No nausea (delayed phase); (6): No nausea (overall phase); (7): Adverse events; (8): Quality of Life. a: 100mg qd (D1-7) and then weekly increase of 100 mg until reaching the tolerated dose. b: 100mg qn (D1) and increase to 200 mg/d within one week, and then the maintenance dose lasts for 3 months. c: 100mg qn (D1-7) and weekly increase of 50 mg until reaching the tolerated dose (400 mg/d is the maximum dose), treatment lasts for at least 3 months.
3.4.2 QoL
Data from 12 out of the 34 included articles examined the impact of THD on QoL and included 4 items: increase in the KPS scores (11 studies), weight gain (7 studies), appetite improvement (6 studies), and sleep quality improvement (4 studies). There was no significant heterogeneity among all studies ($I^2<50\%$) and all analyses were performed using a fixed-effects model.

The incidence of an increase in KPS scores, weight gain, appetite improvement, and sleep quality improvement was significantly higher with the addition of THD: namely, 55.9\% vs 34.7\% (RR 1.61, 95\%CI 1.38-1.88, $p<0.00001$) of an increase in KPS; 49.4\% vs 25.6\% (RR 1.95, 95\%CI 1.55-2.45, $p<0.00001$) of weight gain; 59.7\% vs 41.0\% (RR 1.47, 95\%CI 1.23-1.74, $p<0.00001$) of appetite improvement; and 69.4\% vs 25.9\% (RR 2.66, 95\%CI 1.92-3.69, $p<0.00001$) of sleep quality improvement (Table 3).

4 DISCUSSION
There is evidence that THD should be considered as an effective additional antiemetic medication (40). This meta-analysis suggests that the addition of THD to 5-HT3RA treatment (with or without DEX) is beneficial. Our findings showed that the addition of THD prevents CINV following HEC during the acute, delayed, and overall phase. Among these phases, the THD group had the most significant improvement in CINV during the delayed phase (70.6\% vs 50.4\% and 50.5\% vs 30.0\% in CR and no nausea, respectively).

This meta-analysis also suggests a high safety profile for the use of THD in patients with tumors undergoing HEC. Although the THD group increased the incidence of constipation, peripheral neuropathy, and somnolence, the incidence was significantly lower in mucositis and anorexia. The addition of THD did not increase the incidence of many adverse events (fatigue, headache, diarrhea, rash, hepatorenal damage, and myelosuppression). Researchers speculate that THD protects the oral mucosa by inhibiting NF-kB and supporting epithelial repopulation (41). Chemotherapy-induced intestinal mucositis and delayed diarrhea are associated with AIM2 (absent in melanoma 2) inflammasome activation, while THD eliminates AIM2 signaling and significantly reduces the incidence of drug-induced diarrhea (42). This study shows that there is no statistical difference in the incidence of diarrhea between the THD group and the control group, which may require more rigorous clinical trials and a wider population.

As a complementary drug, THD has been shown to improve QoL in cancer patients in this meta-analysis. THD significantly improves KPS scores, weight, sleep quality, and appetite in cancer patients receiving HEC (55.9\% vs 34.7\%, 49.4\% vs 25.6\%, 59.7\% vs 41.0\%, and 69.4\% vs 25.9\%, respectively). A Cochrane meta-analysis shows that there is insufficient evidence to refute or support the use of THD for the treatment of cachexia in patients with advanced cancer (43). THD combined with megestrol acetate was shown to be effective in terms of appetite, body weight, and QoL (44).
### FIGURE 3 | Meta-analysis on CR (acute phase)

| Study or Subgroup | THD Events | Control Events | Total Events | Total Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|---------------|--------------|--------------|-------------------------------|
| Cui 2011          | 7          | 21            | 28           | 0.5%         | 4.17 [0.97, 17.95]            |
| Li 2016           | 25         | 30            | 55           | 6.4%         | 1.09 [0.84, 1.40]             |
| Song 2017         | 37         | 40            | 77           | 10.4%        | 1.02 [0.90, 1.18]             |
| Yu 2009           | 26         | 30            | 56           | 6.5%         | 1.12 [0.88, 1.42]             |
| Zhang 2016        | 25         | 52            | 77           | 4.2%         | 1.60 [0.96, 2.67]             |
| Zhang 2017        | 245        | 317           | 562          | 64.4%        | 1.06 [0.97, 1.18]             |
| Zuo 2014          | 30         | 41            | 71           | 7.6%         | 1.08 [0.82, 1.44]             |

Total (95% CI): 531 / 540 (100.0%) 1.10 [1.03, 1.18]

Total events: 395 / 364
Heterogeneity: Chi² = 7.39, df = 6 (P = 0.29); I² = 19%
Test for overall effect: Z = 2.64 (P = 0.008)

### FIGURE 4 | Meta-analysis on CR (delayed phase)

| Study or Subgroup | THD Events | Control Events | Total Events | Total Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------|---------------|--------------|--------------|-------------------------------|
| Cheng 2018        | 22         | 45            | 67           | 8.2%         | 1.47 [0.88, 2.44]             |
| Han 2016          | 28         | 40            | 68           | 11.3%        | 1.40 [0.96, 2.04]             |
| Li 2016           | 20         | 30            | 50           | 7.1%         | 2.00 [1.14, 3.52]             |
| Song 2017         | 34         | 40            | 74           | 18.1%        | 1.18 [0.94, 1.48]             |
| Yu 2009           | 16         | 30            | 46           | 4.7%         | 2.36 [1.14, 4.91]             |
| Zhang 2016        | 30         | 52            | 82           | 7.5%         | 2.40 [1.39, 4.15]             |
| Zhang 2017        | 243        | 316           | 559          | 23.8%        | 1.25 [1.12, 1.39]             |
| Zhao 2016         | 32         | 39            | 71           | 12.1%        | 1.78 [1.23, 2.57]             |
| Zuo 2014          | 22         | 41            | 63           | 6.9%         | 1.95 [1.09, 3.48]             |

Total (95% CI): 633 / 637 (100.0%) 1.53 [1.28, 1.82]

Total events: 447 / 321
Heterogeneity: Tau² = 0.03; Chi² = 17.29, df = 8 (P = 0.03); I² = 54%
Test for overall effect: Z = 4.70 (P < 0.000001)

### FIGURE 5 | Meta-analysis on CR (overall phase)

| Study or Subgroup | THD Events | Control Events | Total Events | Total Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|---------------|--------------|--------------|-------------------------------|
| Han 2014          | 29         | 38            | 67           | 8.4%         | 1.36 [0.95, 1.93]             |
| Song 2017         | 34         | 40            | 74           | 12.9%        | 1.18 [0.94, 1.48]             |
| Wang 2018         | 25         | 40            | 65           | 5.6%         | 1.92 [1.16, 3.19]             |
| Zhang 2017        | 209        | 316           | 525          | 73.1%        | 1.24 [1.09, 1.41]             |

Total (95% CI): 434 / 436 (100.0%) 1.28 [1.15, 1.43]

Total events: 297 / 233
Heterogeneity: Chi² = 3.31, df = 3 (P = 0.35); I² = 9%
Test for overall effect: Z = 4.51 (P < 0.000001)
### FIGURE 6 | Meta-analysis on no nausea (acute phase).

| Study or Subgroup | THD | Control | Risk Ratio |
|-------------------|-----|---------|------------|
|                   | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI |
| Jiang 2017        | 87    | 138    | 66     | 128   | 19.2%   | 1.22 [0.99, 1.51] |
| Li 2016           | 22    | 30     | 20     | 30    | 5.6%    | 1.10 [0.79, 1.53] |
| Song 2017         | 34    | 40     | 36     | 43    | 9.7%    | 1.02 [0.84, 1.22] |
| Yu 2009           | 15    | 30     | 9      | 31    | 2.5%    | 1.72 [0.89, 3.32] |
| Zhang 2016        | 22    | 52     | 16     | 50    | 4.6%    | 1.32 [0.79, 2.11] |
| Zhang 2017        | 199   | 317    | 192    | 321   | 53.4%   | 1.05 [0.93, 1.19] |
| Zuo 2014          | 21    | 41     | 18     | 40    | 5.1%    | 1.14 [0.72, 1.79] |

Total (95% CI) 648 643 100.0% 1.12 [1.02, 1.22]

Total events 400 357

Heterogeneity: Chi² = 4.78, df = 6 (P = 0.57); I² = 0%

Test for overall effect: Z = 2.36 (P = 0.02)

### FIGURE 7 | Meta-analysis on no nausea (delayed phase).

| Study or Subgroup | THD | Control | Risk Ratio |
|-------------------|-----|---------|------------|
|                   | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI |
| Jiang 2017        | 71    | 138    | 34     | 128   | 18.3%   | 1.94 [1.39, 2.70] |
| Li 2016           | 17    | 30     | 7      | 30    | 3.6%    | 2.43 [1.18, 4.99] |
| Song 2017         | 32    | 40     | 24     | 43    | 12.0%   | 1.43 [1.05, 1.95] |
| Yu 2009           | 10    | 30     | 3      | 31    | 1.5%    | 3.44 [1.05, 11.31] |
| Zhang 2016        | 33    | 52     | 14     | 50    | 7.4%    | 2.27 [1.39, 3.70] |
| Zhang 2017        | 150   | 317    | 107    | 321   | 55.1%   | 1.42 [1.17, 1.72] |
| Zuo 2014          | 14    | 41     | 4      | 40    | 2.1%    | 3.41 [1.23, 9.49] |

Total (95% CI) 648 643 100.0% 1.69 [1.47, 1.94]

Total events 327 193

Heterogeneity: Chi² = 10.40, df = 6 (P = 0.11); I² = 42%

Test for overall effect: Z = 7.40 (P < 0.00001)

### FIGURE 8 | Meta-analysis on no nausea (overall phase).

| Study or Subgroup | THD | Control | Risk Ratio |
|-------------------|-----|---------|------------|
|                   | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI |
| Jiang 2017        | 61    | 138    | 30     | 128   | 21.2%   | 1.89 [1.31, 2.72] |
| Song 2017         | 30    | 40     | 22     | 43    | 14.5%   | 1.47 [1.04, 2.06] |
| Zhang 2017        | 130   | 317    | 95     | 321   | 64.3%   | 1.39 [1.12, 1.72] |

Total (95% CI) 495 492 100.0% 1.50 [1.27, 1.77]

Total events 221 147

Heterogeneity: Chi² = 2.06, df = 2 (P = 0.36); I² = 3%

Test for overall effect: Z = 4.83 (P < 0.00001)
### TABLE 2 | Meta-analysis on adverse events.

| Adverse Effects   | Number of trials | THD | Control | Heterogeneity analysis | Statistical analysis model | Statistical analysis |
|-------------------|------------------|-----|---------|------------------------|---------------------------|----------------------|
|                   | Events | Total | Incidence | Events | Total | Incidence | Chi² | P   | I² | RR (95%CI) | P   |
| Fatigue           | 12     | 333   | 837 | 39.8% | 303 | 817 | 37.1% | 19.53 | 0.05 | 44% | 1.06 (0.95, 1.18) | 0.3 |
| Constipation      | 26     | 526   | 1333 | 39.5% | 346 | 1285 | 26.9% | 41.59 | 0.02 | 40% | 1.45 (1.30, 1.61) | <0.00001 |
| Mucositis         | 7      | 49    | 336 | 14.6% | 72 | 309 | 23.3% | 4.91 | 0.06 | 0% | 0.64 (0.46, 0.88) | 0.006 |
| Headache          | 5      | 48    | 456 | 10.5% | 52 | 454 | 11.5% | 1 | 0.91 | 0% | 0.91 (0.63, 1.31) | 0.6 |
| Diarrhea          | 7      | 54    | 640 | 8.4% | 42 | 621 | 6.6% | 5.47 | 0.49 | 0% | 1.22 (0.84, 1.76) | 0.3 |
| Rash              | 11     | 55    | 484 | 11.4% | 48 | 466 | 10.3% | 12.24 | 0.27 | 18% | 1.09 (0.76, 1.56) | 0.64 |
| Peripheral neuropathy | 9     | 117   | 427 | 27.4% | 63 | 388 | 16.2% | 7.83 | 0.45 | 0% | 1.61 (1.26, 2.08) | <0.00001 |
| Hepatorenal damage| 13     | 59    | 474 | 12.4% | 51 | 451 | 11.3% | 4.94 | 0.96 | 0% | 1.06 (0.76, 1.48) | 0.72 |
| Somnolence        | 7      | 86    | 260 | 33.1% | 99 | 259 | 38.2% | 7.24 | 0.3 | 17% | 0.88 (0.71, 1.09) | 0.25 |
| Anorexia          | 3      | 22    | 112 | 19.6% | 43 | 115 | 37.4% | 3.84 | 0.15 | 48% | 0.52 (0.34, 0.81) | 0.003 |

### TABLE 3 | Meta-analysis on QoL.

| Quality of Life     | Number of trials | THD | Control | Heterogeneity analysis | Statistical analysis model | Statistical analysis |
|---------------------|------------------|-----|---------|------------------------|---------------------------|----------------------|
|                     | Events | Total | Incidence | Events | Total | Incidence | Chi² | P   | I² | RR (95%CI) | P   |
| Increase in KPS scores | 11     | 227   | 406 | 55.9% | 137 | 395 | 34.7% | 6.42 | 0.78 | 0% | 1.61 (1.38, 1.88) | <0.00001 |
| Weight gain         | 7      | 131   | 265 | 49.4% | 67 | 262 | 25.6% | 5.35 | 0.5 | 0% | 1.95 (1.55, 2.45) | <0.00001 |
| Appetite improvement | 6      | 139   | 233 | 59.7% | 96 | 234 | 41.0% | 1.04 | 0.96 | 0% | 1.47 (1.23, 1.74) | <0.0001 |
| Sleep quality improvement | 4     | 86    | 124 | 69.4% | 30 | 116 | 25.9% | 4.53 | 0.21 | 34% | 2.66 (1.92, 3.69) | <0.00001 |
This study has several strengths. Firstly, we included 34 RCTs and 3168 cases, expanding the scope and number of THD studies and greatly improving sample size and test efficacy. Secondly, we compared the differences in the incidence of 11 adverse events between the THD and control groups to provide a reference for the safety study of THD use in cancer patients. Finally, we also analyzed the effect of THD in increasing KPS scores, increasing weight, improving sleep quality, and increasing appetite from the perspective of QoL of cancer patients.

This meta-analysis also has some limitations. First, although the search for this study was extensive and included both English and Chinese databases, the final population of the literature included in the study was Chinese, which is not representative of other regional populations and ethnicities. Second, many of the studies we included scored poorly on quality assessment, which to some extent affects the final results of the meta-analysis. Finally, the number of studies containing the same outcome was no more than 10, so a funnel plot was not used to test for publication bias.

5 CONCLUSION

According to this systematic review and meta-analysis, we conclude that THD is effective and safe for the prevention of CINV in patients being treated with HEC, and has a significant tendency to improve QoL. More high-quality RCTs with more participants are warranted to support our findings.

REFERENCES

1. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol Off J Am Soc Clin Oncol (2020) 38(24):2782–97. doi: 10.1200/JCO.20.01296
2. Gilmore J, D’Amato S, Griffith N, Schwartzberg L. Recent Advances in Antiemetics: New Formulations of 5HT-Receptor Antagonists. Cancer Manag Res (2018) 10:2018–57. doi: 10.2147/CMAR.S166912
3. Zhang L, Qu X, Teng Y, Shi J, Yu P, Sun T, et al. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 Study). J Clin Oncol Off J Am Soc Clin Oncol (2017) 35(31):3558–65. doi: 10.1200/JCO.2017.72.2538
4. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ (Clin Res Ed) (2009) 339:b2535. doi: 10.1136/bmj.b2535
5. National Cancer Institute and National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0b/CTCAE_5.0b_STAGING.xlsv (Accessed December 24, 2021).
6. Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration J Cochrane Database Systematic Rev (2011) 2011 (14):753–4. doi: 10.1002/14651858.MS06509
7. Cheng Q, Chen Z, Wang N. The Clinical Efficacy of Thalidomide in Preventing Delayed Vomiting Caused by Cisplatin Chemotherapy. China Foreign Med Treat (2018) 37(18):92–4. doi: 10.16662/j.cnki.1674-0742.2018.18.092
8. Wang S. Efficacy of Thalidomide Combined With Palonosetron in the Prevention of Vomiting Induced by Cisplatin Chemotherapy in Lung Cancer Patients. Guide China Med (2018) 16(23):24–5. doi: 10.15912/j.cnki.gcmm.2018.23.013
9. Song G, Wang N, Li FF, Wang NF. Thalidomide for Prevention of Chemotherapy-Induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy. J Australas Med (2017) 10(3):192–8. doi: 10.21767/AMJ.2016.2826
10. Li M, Gao E, Cui F, Chen LQ, Zhang FL. Clinical Study of Thalidomide Combined With Ondansetron in the Prevention of Nausea and Vomiting in Lung Cancer Patients With Chemotherapy. J Mod Oncol (2016) 24(17):2719–23. doi: 10.3969/j.issn.1672-4992.2016.17.014
11. Zhao W, Yu P, Jin X, Qu LJ. Clinical Observation of Thalidomide in the Treatment of Delayed Vomiting Due to Chemotherapy. Chin J Convalescent Med (2016) 25(02):201–2. doi: 10.15317/j.cnki.ccm.2016.02.044
12. Han Z, Sun X, Jiang G, Du XP. Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy. J Coll Physicians Surg Pak (2016) 26(11):900.
13. Han Z, Sun X, Xu J, Li Y, Du X. Clinical Study of Treatment of Peri-Chemotherapy Nausea and Vomiting of Cancer Patients Using Thalidomide. Cancer Res Clin (2014) 26(10):667–9.
14. Zuo C. Effect of Thalidomide Combined With Tropisetron Hydrochloride on Nausea and Vomiting Induced by GP Chemotherapy for Metastatic Breast Cancer. Chin J Clin Res (2014) 27(12):1491–3. doi: 10.13429/j.cnki.cjcr.2014.12.019
15. Cui Y, Li J, Wang WY, Lu CX, Zhou Y, Liu MY. Clinical Observation of Thalidomide Combined With Tropisetron in the Treatment of Vomiting Associated With Adjuvant Chemotherapy for Breast Cancer. J Pract Med (2011) 27(19):3576–8.
16. Yu YL, Zhu ZT, Li JP, Ha MW, Liu XM, Wu Q, et al. The Effect of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by GP Regimen of Chemotherapy for Non-Small Cell Lung Cancer. Chin J Oncol (2009) 31(12):937–40.
17. Zhang J, Kang H, Wang B, Shun GM. The Efficacy and Safety of Palonosetron With Thalidomide to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) During Chemotherapy in Small Cell Lung Cancer Patients. Chin J Clin Oncol Rehabil (2016) 23(08):943–6. doi: 10.13455/j.cnki.cjcor.2016.08.14

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

JX and CZ contributed to study design, literature search, data collection, data analysis, and manuscript drafting. SL and RD contributed to quality assessment and data collection. MS, BD, and QX contributed to critical revision. JW, CS, and YZ contributed to conception, design, supervision, and manuscript drafting. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China [82073402] and Key research and development program of Hubei Province [2020BCA060].

ACKNOWLEDGMENTS

The authors thank all the staff member for their invaluable efforts to this study.
18. Jiang H. Thalidomide for Control Nausea in Cancer Patients Receiving Highly Emetogenic Chemotherapy. ShenYang: China Medical University (2017).

19. Xing A, Zhang N, Liu Y. Effect of Thalidomide Combination Chemotherapy on Serum MMP-9 and VGER Levels in Patients With Gastric Cancer. J Mod Int Med (2019) 40(01):7–4. doi: 10.13799/j.cnki.mjdxxyb.2019.01.024

20. Luo Q. Thalidomide Combined With GP Regimen for Advanced Non-Small Cell Lung Cancer. J Pract Med (2011) 27(06):1080–2. doi: 10.3969/j.issn.1006-5725.2011.06.069

21. Niu K, Deng W, Li N, Luo SX. Efficacy of Thalidomide Combined With Paclitaxel Plus Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer. J Pract Med (2011) 27(05):859–62. doi: 10.3969/j.issn.1006-5725.2011.05.045

22. Peng Y, Wang M, Xie N, Li Y, Lu HY, Li BM. Paclitaxel and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer. J Pract Med (2011) 27(06):1121–3. doi: 10.3969/j.issn.1006-5725.2011.06.069

23. Peng Y, Zhang X, Xie N, Wang MQ, Li BM. Clinical Observation on Therapeutic Effect of Thalidomide in Combination With Paclitaxel Plus Cisplatin Regimen in the Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer. Chin J Diffic Compl Cas (2014) 13(01):49–52. doi: 10.3969/j.cnki.1671-6450.2014.01.018

24. He Q, Yi T, Luo B, Zhang XL. A Randomized Trial of NVB Plus DDP With versus Without Thalidomide in the Treatment of Advanced Non-Small Cell Lung Cancer. Chin J Lung Cancer (2008) 11(02):264–7. doi: 10.3779/j.issn.1009-3419.2008.02.019

25. Zhang Z. Effect of Thalidomide Combined With TP Regimen Chemotherapy on Serum Tumor Markers in Patients With Advanced NSCLC. J Huaihai Med (2019) 37(04):338–40. doi: 10.14126/j.cnki.1008-7044.2019.04.003

26. Zhang X. Effect of Thalidomide Combined With TP Regimen Chemotherapy on Serum Tumor Markers in Patients With Advanced NSCLC. J Huaihai Med (2019) 37(04):338–40. doi: 10.14126/j.cnki.1008-7044.2019.04.003

27. Huang J. Effect of Thalidomide Combination With GP Regimen on Non-Small Cell Lung Cancer and Effects of Serum VEGF. J Mil Surg Southwest China (2012) 14(01):34–5. doi: 10.3969/j.issn.1672-7193.2012.01.017

28. Pujol JL, Breton JL, Gervais R, Tanguy ML, Quox E, Janicot PD, et al. Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC Cleo04 IFC. Ann Oncol 00-01. J Clin Oncol Off J Am Soc Clin Oncol (2007) 25(25):3945–51. doi: 10.1200/jco.2007.11.8109

29. Sun X, Xu J. Clinical Observation of Thalidomide Combined With Docaetaxel and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer. J China Tradit Chin Med Inf (2011) 03(03):159–61.

30. Liang D. Clinical Study on Thalidomide Combined With Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Guangxi: Guanxizi Medical University (2008).

31. Wang J, Jia J, Wang Z, Wang XH. Effect of Thalidomide Combined With Targeted Therapy for Non-Small Cell Lung Cancer Patients on the Survival and Quality of Life. Chin J Med (2017) 52(05):37–40. doi: 10.3969/j.issn.1008-1070.2017.05.012

32. Zuo C. Clinical Observation of Thalidomide Combined With EP Chemotherapy in the Treatment of Extensive Stage Small Cell Lung Cancer. J Basic Clin Oncol (2018) 31(04):329–31. doi: 10.3969/j.cnki.1673-5412.2018.04.015

33. Xie H, Liu H, Wang W. Curative Effect of the GP Combined With Thalidomide in the Treatment of Advanced Triple-Negative Breast Cancer. J Bengbu Med Coll (2017) 42(07):878–80+84. doi: 10.13898/j.cnki.1000-2200.2017.07.012

34. Dong J. Effect of Thalidomide Combined With Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer in the Elderly. World Latest Med Inf (2019) 37(04):338. doi: 10.3969/j.cnki.wlmi.2019.07.010

35. Huang Y, Wu Q. Clinical Study on Thalidomide Combined With TP Scheme in the Treatment of Advanced Non-Small Cell Lung Cancer. China Contin Med Educ (2016) 8(32):160–1. doi: 10.3969/j.issn.1674-9308.2016.32.089

36. Liu F, Li XY, Li FL, Chen DW. To Observe the Effect of Thalidomide in Combination With Paclitaxel Combined With TP Regimen in the Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer. World Latest Med Inf (2015) 15(31):1–2. doi: 10.3969/j.issn.1671-3141.2015.31.001

37. Jiang W, Wang Y, Jiang H, Hu CX, Zhou Y. The Control Clinical Study on the Treatment of Advanced Non-Small Cell Lung Cancer by TGP Regimen and GP Regimen. Chin Clin Oncol (2010) 15(09):798–801.

38. Sun Y, Wang L, Chen W. Clinical Study of Thalidomide Combined With NP Regimen for Advanced Non-Small Cell Lung Cancer. Cancer Res Clin Oncol (2010) 22(01):38–40.

39. Shen Z, Wang C, Liang J, Bi Q, Yang RY. Clinical Research of Thalidomide in Corporation With NP in Treatment of III/IV Lung Cancer. Cancer Res Clin Oncol (2009) 21(10):663–5.

40. Gourd E. Thalidomide Reduces Chemotherapy-Induced Vomiting. Lancet Oncol (2017) 18(10):e570. doi: 10.1016/S1470-2045(17)30676-9

41. Frings K, Gruber S, Kues P, Kleiter M, Dörr W. Modulation of Radiation-Induced Oral Mucositis by Thalidomide: A Preclinical Study. Strahlentherapie und Onkologische Strahlentherapie (2012) 192(8):561–8. doi: 10.1002/sot.20989-5

42. Lian QS, Xu J, Yan SS, Huang M, Ding HH, Sun XY. Chemotherapy-Induced Intestinal Inflammatory Responses Are Mediated by Exosomal Secretion of Double-Strand DNA via AIM2 Inflammasome Activation. Cell Res (2017) 27(6):784–800. doi: 10.1038/cr.2017.54

43. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M. Thalidomide for Managing Cancer Cachexia. Cochrane Database Systematic Rev (2012) 4:CD008664. doi: 10.1002/14651858.CD008664.pub2

44. Wen HS, Li X, Cao YZ, Zhang CC, Yang F, Shi YM, et al. Clinical Studies on the Treatment of Cancer Cachexia With Megestrol Acetate Plus Thalidomide. Chemotherapy (2012) 58(6):461–7. doi: 10.1159/000346446

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xie, Zhang, Li, Dai, Sullivan, Deng, Xu, Wang, Shi and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.